Xencor, Inc Paid-in-Kind Interest
Xencor, Inc (XNCR) reported Paid-in-Kind Interest of $12.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-05
- Xencor, Inc paid-in-kind interest for the quarter ending 2026-06-30 was $7.35M, a 10.85% decline year-over-year.
- Xencor, Inc paid-in-kind interest for the quarter ending 2026-03-31 was $4.70M, a 45.75% decline year-over-year.
- Xencor, Inc paid-in-kind interest for the quarter ending 2025-12-31 was $7.35M, a 14.94% decline year-over-year.
- Xencor, Inc paid-in-kind interest for the quarter ending 2025-09-30 was $7.66M, a 14.98% decline year-over-year.
- Xencor, Inc paid-in-kind interest for fiscal 2025 was $31.92M, a 12.77% decline from fiscal 2024.
- Xencor, Inc paid-in-kind interest for fiscal 2024 was $36.59M, a 494.72% increase from fiscal 2023.
- Xencor, Inc paid-in-kind interest for fiscal 2023 was $6.15M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 3 month as first filed | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 6 month as first filed | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $12.05M 10-Q · filed 2026-08-05 | $19.40M derived: sum of 3 quarters · filed 2026-08-05 | $27.06M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $4.70M 10-Q · filed 2026-05-06 | $12.05M derived: sum of 2 quarters · filed 2026-05-06 | $19.71M derived: sum of 3 quarters · filed 2026-05-06 | $27.96M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.02M derived: sum of 2 quarters · filed 2026-02-25 | $23.26M derived: sum of 3 quarters · filed 2026-08-05 | $31.92M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $7.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.90M derived: sum of 2 quarters · filed 2026-08-05 | $24.57M 10-Q · filed 2025-11-05 | $33.21M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $8.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $16.91M 10-Q · filed 2026-08-05 | $25.55M derived: sum of 3 quarters · filed 2026-08-05 | $34.56M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $8.66M 10-Q · filed 2026-05-06 | $17.31M derived: sum of 2 quarters · filed 2026-05-06 | $26.32M derived: sum of 3 quarters · filed 2026-05-06 | $35.59M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $17.66M derived: sum of 2 quarters · filed 2026-02-25 | $26.93M derived: sum of 3 quarters · filed 2026-02-25 | $36.59M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $9.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $18.29M derived: sum of 2 quarters · filed 2025-11-05 | $27.95M 10-Q · filed 2025-11-05 | $2.68M 10-Q · filed 2024-11-06 | $34.10M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | $9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $18.94M 10-Q · filed 2025-08-06 | $1.90M 10-Q · filed 2024-08-05 | $25.09M derived: sum of 3 quarters · filed 2026-02-25 | $25.09M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $9.66M 10-Q · filed 2025-05-07 | $1.07M 10-Q · filed 2024-05-09 | $15.82M derived: sum of 2 quarters · filed 2026-02-25 | $15.82M derived: sum of 3 quarters · filed 2026-02-25 | $15.82M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | $6.15M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $6.15M derived: sum of 2 quarters · filed 2026-02-25 | $6.15M derived: sum of 3 quarters · filed 2026-02-25 | $6.15M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | ||||
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | |||||
| 2023-03-31 | $0.00 10-Q/A · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |